Biofrontera (BFRI) to Release Earnings on Thursday

Biofrontera (NASDAQ:BFRI) is expected to be releasing its Q4 2025 results after the market closes on Thursday, March 19th. Analysts expect the company to announce earnings of $0.29 per share and revenue of $16.1460 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 19, 2026 at 10:00 AM ET.

Biofrontera Stock Up 1.9%

BFRI opened at $0.85 on Thursday. The stock has a market cap of $9.86 million, a PE ratio of -0.52 and a beta of 0.61. Biofrontera has a 52 week low of $0.54 and a 52 week high of $1.19. The business’s fifty day simple moving average is $0.86 and its 200 day simple moving average is $0.88.

Wall Street Analysts Forecast Growth

Separately, Benchmark reissued a “buy” rating on shares of Biofrontera in a report on Friday, November 14th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Biofrontera presently has a consensus rating of “Hold” and a consensus price target of $2.75.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Biofrontera stock. Geode Capital Management LLC boosted its stake in Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the period. Geode Capital Management LLC owned about 0.56% of Biofrontera worth $37,000 at the end of the most recent reporting period. 10.08% of the stock is currently owned by institutional investors.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.